TABLE 1.
Patient characteristics
| Value | |
|---|---|
| No. of patients | 86 |
| Sex | |
| Female | 39 (45.3) |
| Male | 47 (54.7) |
| Age, yrs | |
| Median (range) | 13 (1–21) |
| Mean | 12.2 |
| Brain tumor type | |
| Primary | 84 (97.7) |
| Metastatic | 2 (2.3) |
| Pathology diagnosis | |
| Biopsy proven | 64 (74.4) |
| Presumed | 22 (25.6) |
| Tumor grade | |
| Low (I or II) | 76 |
| High (III or IV) | 10 |
| Pre-SLA cranial surgery | |
| Related to TOI | 28 (32.6) |
| Not related to TOI | 13 (15.1) |
| Tumor location | |
| Frontal lobe | 11 (12.8) |
| Temporal lobe (neocortical) | 3 (3.5) |
| Temporal lobe (mesial) | 10 (11.6) |
| Parietal lobe | 6 (7) |
| Occipital lobe | 3 (3.5) |
| Thalamus | 10 (11.6) |
| Hypothalamus | 6 (7.0) |
| Basal ganglia | 6 (7.0) |
| Periventricular | 17 (19.8) |
| Cerebellar | 14 (16.3) |
| SLA system used | |
| Visualase | 67 (78) |
| NeuroBlate | 19 (22) |
| Targeting system used | |
| Frameless | 22 (25.6) |
| Framed | 43 (50) |
| Robotic | 21 (24.4) |
| Pre-SLA neurological symptom or deficit | |
| Yes | 50 (58.1) |
| No | 36 (41.9) |
| Presenting symptom post-SLA (n = 77) | |
| Stable | 45 (58.4) |
| Improved | 28 (36.4) |
| Worsened | 4 (5.2) |
Values represent the number of patients (%) unless stated otherwise. Percent-ages are based on 86 patients unless noted otherwise.